G Zulian
Palliative care education in Swiss undergraduate medical curricula: a case of too little, too early
Pereira J, Pautex S, Cantin B, Gudat H, Zaugg K, Zulian G, Eychmuller S. Palliative care education in Swiss undergraduate medical curricula: a case of too little, too early. Palliative medicine 2008; 22:730-5.
01.09.2008Palliative care education in Swiss undergraduate medical curricula: a case of too little, too early
01.09.2008Palliative medicine 2008; 22:730-5
Pereira J, Pautex S, Cantin B, Gudat H, Zaugg K, Zulian G, Eychmuller Steffen
Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study
von Rohr A, Tobler A, Betticher D, Cerny T, Fey M, Racine C, Rufener B, Ghielmini M, Zulian G, Konwalinka G, Frickhofen N, Wernli M, Piguet D, Hess U, Tichelli A, Schmitz S, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002; 13:1641-9.
01.10.2002Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a phase II study
01.10.2002Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002; 13:1641-9
von Rohr A, Tobler A, Betticher D, Cerny Thomas, Fey M F, Racine C, Rufener B, Ghielmini M, Zulian G, Konwalinka G, Frickhofen N, Wernli M, Piguet D, Hess U, Tichelli A, Schmitz S-F H, Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK)
Morant R, Hürny C, Hanselmann S, Zulian G, Bauer J, Trinkler F, Jacky E, Thürlimann B, Fey M, Borner M, Maibach R, Bernhard J, Hering F. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:183-8.
01.02.2000Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK)
01.02.2000Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000; 11:183-8
Morant R, Hürny C, Hanselmann S, Zulian G, Bauer J, Trinkler F, Jacky E, Thürlimann Beat, Fey M F, Borner M, Maibach R, Bernhard J, Hering F